A. Patterson

发表

Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade.

P. Schellhammer, G. Haas, E. Klein, 1997, The Journal of urology.

Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy.

D. Kapoor, R. Echols, E. Whalen, 1998, Urology.

Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues

P. Schellhammer, N. Vogelzang, M. Soloway, 1999, The Prostate.

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1995, Urology.

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone–Releasing hormone analogue therapy, in patients with advanced prostate carcinoma: Analysis of time to progression

P. Schellhammer, N. Vogelzang, Yusong Chen, 1996, Cancer.

Bladder cancer. Clinical practice guidelines in oncology.

J. Richie, P. Lange, J. Montie, 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

Comparison of goserelin and leuprolide in combined androgen blockade therapy.

P. Schellhammer, E. Klein, N. Vogelzang, 1998, Urology.

NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.

A. Kishan, V. Margulis, S. Boorjian, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Osteoporosis and fractures after androgen deprivation initiation for prostate cancer.

I. Derweesh, R. Wake, J. Malcolm, 2007, The Canadian journal of urology.

Bladder Cancer, Version 2.2016 Featured Updates to the NCCN Guidelines

Geoffrey E. Wile, A. Kibel, S. Boorjian, 2016 .

Risk of new‐onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen‐deprivation therapy for prostate cancer

I. Derweesh, A. Kitabchi, R. Wake, 2007, BJU international.

Penile cancer: Clinical Practice Guidelines in Oncology.

Geoffrey E. Wile, J. Richie, D. Kuban, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Comparison of rates and risk factors for development of osteoporosis and fractures after radical or partial nephrectomy.

I. Derweesh, C. Kane, J. Wan, 2011, Urology.

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Geoffrey E. Wile, A. Kibel, S. Boorjian, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

Bladder Cancer , Version 5 . 2017 Clinical Practice Guidelines in Oncology

Geoffrey E. Wile, S. Boorjian, N. Agarwal, 2017 .

Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer

I. Derweesh, R. Wake, J. Malcolm, 2008, BJU international.

Bicalutamide and Flutamide, Each in Combination with Luteinizing Hormone-Releasing Hormone Analogs, in Advanced Prostate Cancer: Exploratory Analysis of Impact of Extent of Disease by Bone Scan on Outcome

P. Schellhammer, N. Vogelzang, M. Soloway, 2000 .

Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer.

R. Bahnson, R. Greenberg, M. Israel, 2000, Urology.

RENAL nephrometry score is associated with operative approach for partial nephrectomy and urine leak.

I. Derweesh, K. Palazzi, R. Mehrazin, 2012, Urology.

Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

S. Boorjian, N. Agarwal, Sam S. Chang, 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Anthony Patterson, Mark K Buyyounouski, Khurshid A Guru, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Bladder cancer.

Geoffrey E. Wile, J. Richie, D. Kuban, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Bladder cancer, version 3.2020

S. Boorjian, N. Agarwal, Sam S. Chang, 2020 .

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1997, Urology.

A controlled trial of Casodex (bicalutamide) vs. flutamide, each in combination with luteinising hormone-releasing hormone analogue therapy in patients with advanced prostate cancer. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1996, European urology.

Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.

P. Schellhammer, N. Vogelzang, M. Soloway, 1996, Urology.

Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.

Anthony Patterson, Mark K Buyyounouski, Khurshid A Guru, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Feasibility and efficacy of neoadjuvant sunitinib before nephron‐sparing surgery

I. Derweesh, C. Kane, R. Mehrazin, 2010, BJU international.

Does radical nephrectomy increase the risk of erectile dysfunction compared with partial nephrectomy? A cohort analysis

I. Derweesh, I. Goldstein, C. Kane, 2013, BJU international.

Survival outcomes after radical and partial nephrectomy for clinical T2 renal tumours categorised by R.E.N.A.L. nephrometry score

I. Derweesh, K. Palazzi, R. Mehrazin, 2014, BJU international.

Analysis of Renal Functional Outcomes After Radical or Partial Nephrectomy for Renal Masses ≥7 cm Using the RENAL Score.

I. Derweesh, K. Palazzi, J. Wan, 2015, Urology.

Survival outcomes in men receiving androgen‐deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20‐year single‐centre experience

I. Derweesh, J. Wan, R. Wake, 2009, BJU international.

Risk factors for bladder tumors in spinal cord injury patients.

R. Dmochowski, C. Cox, W H Stonehill, 1996, The Journal of urology.

Comparison of rates and risk factors for development of anaemia and erythropoiesis‐stimulating agent utilization after radical or partial nephrectomy

I. Derweesh, C. Kane, J. Wan, 2012, BJU international.

Comparison of rates and risk factors for developing chronic renal insufficiency, proteinuria and metabolic acidosis after radical or partial nephrectomy

I. Derweesh, R. Mehrazin, A. Bagrodia, 2009, BJU international.

Single-dose oral ciprofloxacin compared with cefotaxime and placebo for prophylaxis during transurethral surgery.

R. Echols, E. Whalen, S. Kowalsky, 1999, The Journal of antimicrobial chemotherapy.

Prevalence and predictive factors for the development of de novo psychiatric illness in patients receiving androgen deprivation therapy for prostate cancer.

I. Derweesh, R. Wake, J. Malcolm, 2008, The Canadian journal of urology.

Bladder cancer. Clinical guidelines in oncology.

J. Richie, P. Lange, J. Montie, 2006, Journal of the National Comprehensive Cancer Network : JNCCN.

Does timing of cytoreductive nephrectomy impact patient survival with metastatic renal cell carcinoma in the tyrosine kinase inhibitor era? A multi-institutional study.

Samuel K. Park, I. Derweesh, C. Kane, 2013, Urology.

Erattum: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial (Urology (September 1997) 50 (330-336))

P. Schellhammer, N. Vogelzang, M. Soloway, 1998 .

Impact of tumour morphology on renal function decline after partial nephrectomy

Michael A Liss, Samuel K. Park, I. Derweesh, 2013, BJU international.

Estimated potency of casodex: A problematic design [1] (multiple letters)

P. Schellhammer, J. Simard, N. Vogelzang, 1997 .

Variation in the incidence of and risk factors for the development of nephrolithiasis after radical or partial nephrectomy

I. Derweesh, R. Mehrazin, A. Bagrodia, 2010, BJU international.

Factors affecting renal function after open partial nephrectomy-a comparison of clampless and clamped warm ischemic technique.

I. Derweesh, K. Palazzi, R. Mehrazin, 2012, Urology.

Rising Serum Uric Acid Level Is Negatively Associated with Survival in Renal Cell Carcinoma

I. Derweesh, R. Mehrazin, R. McKay, 2019, Cancers.

Statin utilization improves oncologic and survival outcomes in patients with dyslipidemia and surgically treated renal cell carcinoma.

I. Derweesh, R. Mehrazin, A. Bagrodia, 2017, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

NCCN Guidelines Insights: Bladder Cancer, Version 2.2016.

Geoffrey E. Wile, A. Kibel, S. Boorjian, 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018.

Geoffrey E. Wile, S. Boorjian, N. Agarwal, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Nomogram to Predict Prostate Cancer Diagnosis on Primary Transrectal Ultrasound-Guided Prostate Biopsy in a Contemporary Series

M. Kattan, I. Derweesh, Michael M. Maddox, 2012, Current Urology.

Impact of renal surgery for cortical neoplasms on lipid metabolism

I. Derweesh, C. Kane, J. Wan, 2014, BJU international.

Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer

I. Derweesh, R. Wake, J. Malcolm, 2008, BJU international.

Survival outcomes in men receiving androgen‐deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20‐year single‐centre experience

I. Derweesh, R. Wake, J. Malcolm, 2009, BJU international.

Penile cancer: Clinical Practice Guidelines in Oncology.

Geoffrey E. Wile, J. Richie, D. Kuban, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.